LILRB2 and non-small cell lung carcinoma: Furthermore, LILRB2 blockade in preclinical NSCLC models reduced granulocytic myeloid-derived suppressor cell (MDSC) and Treg infiltration and skewed tumor-associated myeloid cells toward a more inflammatory immune phenotype, with enhanced antitumor activity (57).